Theonys: Funding, Investors & Team (Sep 2026)
Theonys is a patient-focused drug discovery company that's harnessing the power of tRNA to pioneer an entirely new class of genomic medicines. The company is advancing Precision Translational Reprogramming as a novel approach to treating complex, multigenic diseases like cancer. The company was launched in 2020 by Nick Davis and Pete Dedon at MIT, Richard Gregory at Harvard, and Tom Begley at UAlbany — world experts in tRNA network biology and cancer — and is headquartered in Cambridge, Massachusetts.
Theonys has raised $2.9M across 1 funding round on record, the most recent an undisclosed round of $2.9M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Theonys Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Theonys Funding Rounds
Theonys Founders and Leadership Team
No contact details are on record for this team yet.
Theonys Funding Compared to Other Biotechnology Startups
Theonys' latest round of $2.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Theonys in Biotechnology and Cambridge
Companies Similar to Theonys
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Theonys Funding FAQs
What does Theonys do?
Theonys is a patient-focused drug discovery company that's harnessing the power of tRNA to pioneer an entirely new class of genomic medicines. The company is advancing Precision Translational Reprogramming as a novel approach to treating complex, multigenic diseases like cancer. The company was launched in 2020 by Nick Davis and Pete Dedon at MIT, Richard Gregory at Harvard, and Tom Begley at UAlbany — world experts in tRNA network biology and cancer — and is headquartered in Cambridge, Massachusetts.
How much funding has Theonys raised?
Theonys has raised $2.9M across 1 round on record. The most recent is an undisclosed round of $2.9M announced in Aug 2022.
When did Theonys last raise funding?
Theonys' most recent funding round on record is an undisclosed round of $2.9M, announced in Aug 2022.
Who is the CEO of Theonys?
Nick Davis is listed as CEO at Theonys.
Where is Theonys headquartered?
Theonys is based in Cambridge, Massachusetts, United States.
How many employees does Theonys have?
Theonys is in the 11-50 employee band.
How does Theonys' funding compare to other Biotechnology startups?
Theonys' latest round of $2.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Theonys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Theonys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.